Page 1

Dimerix For Immediate Release DIMERIX QUARTERLY ACTIVITIES REPORT Quarter highlights • REMAP - CAP Phase 3 clinical study in patients with COVID - 19 progresses • DMX - 200 FSGS competitive position further enhanced • CLARITY 2.0 Phase 3 clinical study progresses in patients with COVID - 19 • Dimerix plans for next study in Diabetic Kidney Disease • Major Shareholder loan for $ 5 Million • Cash position of $ 8.5 million at 31 March 2021 ( $ 4.9 million at 31 December 2020 ) only For personal use MELBOURNE , Australia , 08 April 2021 : Dimerix Limited ( ASX : DXB ) ( " Dimerix " or the " Company " ) , a clinical - stage biopharmaceutical company , today announced its Appendix 4C and Quarterly Activities Report for the period ended 31 March 2021. During the quarter , Dimerix made significant operational progress , in line with the strategic plan . Dimerix ended the quarter with cash of $ 8.5 million ( $ 4.9 million at 31 December 2020 ) , with net operating cash outflows for the period of $ 1.4 million , which was in line with company expectations ( $ 0.7 million net operating cash inflows in the prior quarter ) . The increase in total operating cash outflow for the quarter relative to the prior period is a result of increased clinical and manufacturing expenditure and the receipt in the prior quarter of the R & D Tax Incentive rebate for the 2019/2020 financial year ( $ 2.3 million ) . The company's cash position was significantly bolstered with a A $ 5M loan received from a major shareholder , which provides sufficient funding for Dimerix to progress current initiatives , in particular the FSGS Phase 3 program activities , and contributing to a total net cash inflow for the quarter of $ 3.6 million . Dimerix is focused on building shareholder value by advancing clinical trials to provide treatments globally for patients with serious and life - threatening diseases , with two Phase 3 clinical trials in COVID - 19 patients underway and one Phase 3 clinical study in FSGS expected to commence mid - 2021 . Cost management remains a key priority for the business , with the cost base being carefully managed to ensure delivery of a sustainable business beyond the current milestones . In accordance with Listing Rule 4.7C , payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors ' fees , salaries and superannuation . Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs Dimerix HQ 425 Smith St , Fitzroy 3065 Victoria , Australia T. 1300 813 321 E. investor@dimerix.com